202 related articles for article (PubMed ID: 21214672)
1. Evaluation of Aurora kinase inhibition as a new therapeutic strategy in anaplastic and poorly differentiated follicular thyroid cancer.
Wunderlich A; Fischer M; Schlosshauer T; Ramaswamy A; Greene BH; Brendel C; Doll D; Bartsch D; Hoffmann S
Cancer Sci; 2011 Apr; 102(4):762-8. PubMed ID: 21214672
[TBL] [Abstract][Full Text] [Related]
2. Targeting the proteasome as a promising therapeutic strategy in thyroid cancer.
Wunderlich A; Arndt T; Fischer M; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
J Surg Oncol; 2012 Mar; 105(4):357-64. PubMed ID: 22006286
[TBL] [Abstract][Full Text] [Related]
3. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
Wang Z; Chakravarty G; Kim S; Yazici YD; Younes MN; Jasser SA; Santillan AA; Bucana CD; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Aug; 12(15):4755-65. PubMed ID: 16899627
[TBL] [Abstract][Full Text] [Related]
4. Combined inhibition of cellular pathways as a future therapeutic option in fatal anaplastic thyroid cancer.
Wunderlich A; Roth S; Ramaswamy A; Greene BH; Brendel C; Hinterseher U; Bartsch DK; Hoffmann S
Endocrine; 2012 Dec; 42(3):637-46. PubMed ID: 22477151
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.
Manfredi MG; Ecsedy JA; Meetze KA; Balani SK; Burenkova O; Chen W; Galvin KM; Hoar KM; Huck JJ; LeRoy PJ; Ray ET; Sells TB; Stringer B; Stroud SG; Vos TJ; Weatherhead GS; Wysong DR; Zhang M; Bolen JB; Claiborne CF
Proc Natl Acad Sci U S A; 2007 Mar; 104(10):4106-11. PubMed ID: 17360485
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.
Altmann A; Markert A; Askoxylakis V; Schöning T; Jesenofsky R; Eisenhut M; Haberkorn U
J Nucl Med; 2012 Nov; 53(11):1764-71. PubMed ID: 23055533
[TBL] [Abstract][Full Text] [Related]
7. MLN8054, an inhibitor of Aurora A kinase, induces senescence in human tumor cells both in vitro and in vivo.
Huck JJ; Zhang M; McDonald A; Bowman D; Hoar KM; Stringer B; Ecsedy J; Manfredi MG; Hyer ML
Mol Cancer Res; 2010 Mar; 8(3):373-84. PubMed ID: 20197380
[TBL] [Abstract][Full Text] [Related]
8. AZD1152 negatively affects the growth of anaplastic thyroid carcinoma cells and enhances the effects of oncolytic virus dl922-947.
Libertini S; Abagnale A; Passaro C; Botta G; Barbato S; Chieffi P; Portella G
Endocr Relat Cancer; 2011 Feb; 18(1):129-41. PubMed ID: 21071467
[TBL] [Abstract][Full Text] [Related]
9. The dual Aurora kinase inhibitor ZM447439 prevents anaplastic thyroid cancer cell growth and tumorigenicity.
Baldini E; Tuccilli C; Prinzi N; Sorrenti S; Antonelli A; Gnessi L; Catania A; Moretti C; Mocini R; Carbotta G; Morrone S; Persechino S; Redler A; De Antoni E; D' Armiento M; Ulisse S
J Biol Regul Homeost Agents; 2013; 27(3):705-15. PubMed ID: 24152827
[TBL] [Abstract][Full Text] [Related]
10. Identification of Polo-like kinase 1 as a potential therapeutic target in anaplastic thyroid carcinoma.
Nappi TC; Salerno P; Zitzelsberger H; Carlomagno F; Salvatore G; Santoro M
Cancer Res; 2009 Mar; 69(5):1916-23. PubMed ID: 19223553
[TBL] [Abstract][Full Text] [Related]
11. Effects of the Aurora kinases pan-inhibitor SNS-314 mesylate on anaplastic thyroid cancer derived cell lines.
Baldini E; Sorrenti S; D'Armiento E; Guaitoli E; Morrone S; D'Andrea V; Gnessi L; Moretti C; Antonelli A; Catania A; De Antoni E; Ulisse S
Clin Ter; 2012; 163(5):e307-13. PubMed ID: 23099978
[TBL] [Abstract][Full Text] [Related]
12. The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model.
Gomez-Rivera F; Santillan-Gomez AA; Younes MN; Kim S; Fooshee D; Zhao M; Jasser SA; Myers JN
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4519-27. PubMed ID: 17671138
[TBL] [Abstract][Full Text] [Related]
13. The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases.
Emanuel S; Rugg CA; Gruninger RH; Lin R; Fuentes-Pesquera A; Connolly PJ; Wetter SK; Hollister B; Kruger WW; Napier C; Jolliffe L; Middleton SA
Cancer Res; 2005 Oct; 65(19):9038-46. PubMed ID: 16204078
[TBL] [Abstract][Full Text] [Related]
14. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
[TBL] [Abstract][Full Text] [Related]
15. Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.
Wunderlich A; Khoruzhyk M; Roth S; Ramaswamy A; Greene BH; Doll D; Bartsch DK; Hoffmann S
J Surg Res; 2013 Dec; 185(2):676-83. PubMed ID: 23845866
[TBL] [Abstract][Full Text] [Related]
16. Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with NVP-AEE788 for the treatment of aggressive follicular thyroid cancer.
Younes MN; Yazici YD; Kim S; Jasser SA; El-Naggar AK; Myers JN
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3425-34. PubMed ID: 16740767
[TBL] [Abstract][Full Text] [Related]
17. Aplidin reduces growth of anaplastic thyroid cancer xenografts and the expression of several angiogenic genes.
Straight AM; Oakley K; Moores R; Bauer AJ; Patel A; Tuttle RM; Jimeno J; Francis GL
Cancer Chemother Pharmacol; 2006 Jan; 57(1):7-14. PubMed ID: 16001179
[TBL] [Abstract][Full Text] [Related]
18. A cyclin-dependent kinase inhibitor, dinaciclib in preclinical treatment models of thyroid cancer.
Lin SF; Lin JD; Hsueh C; Chou TC; Wong RJ
PLoS One; 2017; 12(2):e0172315. PubMed ID: 28207834
[TBL] [Abstract][Full Text] [Related]
19. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
20. Biological role and potential therapeutic targeting of the chemokine receptor CXCR4 in undifferentiated thyroid cancer.
De Falco V; Guarino V; Avilla E; Castellone MD; Salerno P; Salvatore G; Faviana P; Basolo F; Santoro M; Melillo RM
Cancer Res; 2007 Dec; 67(24):11821-9. PubMed ID: 18089812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]